European Union - English - EMA (European Medicines Agency)

astellas pharma gmbh - tacrolimus - dermatitis, atopic - other dermatological preparations - treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. treatment of moderate to severe atopic dermatitis in children (2 years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids.maintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i.e. occurring 4 or more times per year) who have had an initial response to a maximum of 6 weeks treatment of twice daily tacrolimus ointment (lesions cleared, almost cleared or mildly affected).

European Union - English - EMA (European Medicines Agency)

astellas pharma europe b.v. - tacrolimus - graft rejection - immunosuppressants - prophylaxis of transplant rejection in adult and paediatric, kidney, liver or heart allograft recipients.treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult and paediatric patients.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

astellas pharma ltd - tacrolimus monohydrate - modified-release capsule - 500microgram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

astellas pharma ltd - tacrolimus monohydrate - modified-release capsule - 1mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

astellas pharma ltd - tacrolimus monohydrate - modified-release capsule - 5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

astellas pharma ltd - tacrolimus monohydrate - modified-release capsule - 3mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

astellas pharma ltd - fidaxomicin - tablet - 200mg

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - mirabegron, quantity: 50 mg - tablet, modified release - excipient ingredients: macrogol 2000000; macrogol 8000; purified water; butylated hydroxytoluene; hyprolose; magnesium stearate; hypromellose; iron oxide yellow - symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence in patients with overactive bladder (oab) syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - mirabegron, quantity: 25 mg - tablet, modified release - excipient ingredients: butylated hydroxytoluene; magnesium stearate; hyprolose; purified water; macrogol 2000000; macrogol 8000; hypromellose; iron oxide yellow; iron oxide red - symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence in patients with overactive bladder (oab) syndrome.

Israel - English - Ministry of Health

astellas pharma international b.v., israel - tacrolimus - capsules - tacrolimus 1 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients.treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.